Cited by 2Enzyme function and inhibitionPhysical Organic Chemistry and Reaction KineticsBiochemical and Molecular Research

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Phosphorylation strongly affects the inhibition of human carbonic anhydrase I CO2 hydration activity

Open access
Angeli, Andrea, De Luca, Vivian, Huang, Xiaojing, Winter, Daniel L., Capasso, Clemente, Supuran, Claudiu T., Donald, William A.·2024·Archives of Biochemistry and Biophysics

Published version of a preprint

Abstract

Human carbonic anhydrases (hCAs) have essential roles in respiration, acid-base balance, and fluid secretion, with implications in diseases such as glaucoma, epilepsy, obesity, and cancer. Of the fifteen known hCAs, human CA I (hCA I) is particularly abundant in erythrocytes, playing a critical role in CO2 transport. Despite extensive research on hCA I, the impact of post-translational modifications (PTMs), particularly phosphorylation, on its catalytic activity and inhibitor binding remains poorly understood. Although multiple phosphorylation sites have been identified in hCA I in vivo through high-throughput proteomics studies including at the highly conserved Ser51 residue, the functional consequences of these modifications are not well characterized. We investigated the effects of a phosphomimic mutation at Ser51 on hCA I, examining its catalytic efficiency and susceptibility to inhibition by sulfonamides and anions. Using a recombinant expression system and a stopped-flow kinetic assay, we characterized the CO2 hydration activity and inhibition profiles of S51E hCA I compared to the wild type enzyme. Our results demonstrate that the S51E mutation increases the catalytic turnover rate (kcat) from 2.0 × 105 s-1 to 2.6 × 105 s-1 but significantly decreases substrate affinity, raising the Michaelis constant (KM) from 4.0 mM to 13.9 mM, reducing overall catalytic efficiency by over 50%. Inhibition studies with a panel of 41 sulfonamides revealed that the S51E mutation dramatically alters inhibitor sensitivity, particularly for the most effective inhibitors. For example, 15 of the 16 most effective sulfonamide inhibitors for hCA I (with KIs <350 nM) were an average of over 35-fold less effective in inhibiting S51E hCA I than the wild type. For example, the KI of the anticonvulsant zonisamide increased from 31 nM for the wild type hCA I to 4 µM. The inhibition profile with a panel of 37 small anions further indicated that the S51E mutant exhibited significantly reduced susceptibility to inhibition by 24 out of 37 tested anions, with some KI values increasing by up to 11,000-fold for inhibitors like hydrogen sulfide. This study underscores the significant impact that phosphorylation may have on hCA I function and inhibition. By characterizing the effects of phosphorylation on the CO2 hydration activity and inhibitor sensitivity of hCA I, these findings represent early steps in developing more selective proteoform-specific inhibitors, which could lead to more effective treatments for diseases involving carbonic anhydrases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.abb.2024.110182

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 21

  1. Supuran, 2016, Biochem. J., 473, 2023, 10.1042/BCJ20160115 · DOI
  2. Supuran, 2008, Nat. Rev. Drug Discov., 7, 168, 10.1038/nrd2467 · DOI
  3. Angeli, 2020, Metabolites, 10
  4. Vullo, 2017, Molecules, 22, 10.3390/molecules22030421 · DOI
  5. Supuran, 2021, Clin. Sci., 135, 1233, 10.1042/CS20210040 · DOI
  6. Nocentini, 2021, J. Enzym. Inhib. Med. Chem., 36, 561, 10.1080/14756366.2021.1882453 · DOI
  7. Di Fiore, 2020, J. Enzym. Inhib. Med. Chem., 35, 1450, 10.1080/14756366.2020.1781846 · DOI
  8. Di Fiore, 2022, Amino Acids, 54, 543, 10.1007/s00726-021-03063-y · DOI
  9. Huang, 2023, Int. J. Mol. Sci., 24
  10. Bilbrough, 2022, Chem. Soc. Rev., 51, 5691, 10.1039/D1CS00991E · DOI
  11. Chakravarty, 1994, J. Mol. Biol., 243, 298, 10.1006/jmbi.1994.1655 · DOI
  12. Sugiyama, 2019, Sci. Rep., 9, 10.1038/s41598-019-46385-4 · DOI
  13. Poll, 2024, Cell Commun. Signal., 22, 137, 10.1186/s12964-023-01436-2 · DOI
  14. Raum, 2023, Cell. Mol. Life Sci., 80, 286, 10.1007/s00018-023-04936-z · DOI
  15. Fenwick, 2014, Nat. Commun., 5, 4070, 10.1038/ncomms5070 · DOI
  16. Hackney, 2013, Biophys. J., 104, 652a, 10.1016/j.bpj.2012.11.3602 · DOI
  17. Vullo, 2020, Metabolites, 10
  18. Narumi, 1974, Biochim. Biophys. Acta Enzymol., 350, 215, 10.1016/0005-2744(74)90219-8 · DOI
  19. Toby, 2016, vol. 9, 499
  20. Khalifah, 1971, J. Biol. Chem., 246, 2561, 10.1016/S0021-9258(18)62326-9 · DOI
  21. Cheng, 1973, Biochem. Pharmacol., 22, 3099, 10.1016/0006-2952(73)90196-2 · DOI · Paper page

Metadata

Authors
Angeli, A., De Luca, V., Huang, X., Winter, D. L., Capasso, C., Supuran, C. T., & Donald, W. A.
Affiliations
  • University of Florence (IT)
  • UNSW Sydney (AU)
  • Institute of Biosciences and Bioresources (IT)
Corresponding author
  • Capasso, Clemente
  • Supuran, Claudiu T.
  • Donald, William A.
Venue
Archives of Biochemistry and Biophysics
Publisher
Elsevier BV
Published
2024-11
Volume
761
Pages
110182
ISSN
0003-9861 (ISSN-L)
OpenAlex
W4403424423
Cited by
2
References
1
Citations by year
2026: 2
FWCI
0.27
Type
journal article
Language
en
Open access
Locations
  • Archives of Biochemistry and Biophysics (publishedVersion, cc-by)
  • ChemRxiv (acceptedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Florence Research (University of Florence) (submittedVersion, cc-by)
  • Florence Research (University of Florence) (submittedVersion)
Funders
Australian Research Council (FT200100798)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
  • Physical Sciences › Chemistry › Organic Chemistry › Physical Organic Chemistry and Reaction Kinetics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
Keywords
human carbonic anhydrase I, phosphorylation, CO2 hydration, catalytic efficiency, sulfonamide inhibitors, zonisamide, anion inhibition, hydrogen sulfide, post-translational modification, enzyme inhibition kinetics, substrate affinity, antiepileptic drugs
MeSH terms
Carbon Dioxide, Carbonic Anhydrase Inhibitors, Humans, Kinetics, Mutation, Phosphorylation, Sulfonamides, Water, Carbonic Anhydrase I

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review